Arcturus Therapeutics

Arcturus Therapeutics is a biotechnology company that specializes in the development of RNA medicines. The company's primary focus is on rare diseases, viral infections, and liver diseases. Arcturus Therapeutics utilizes a proprietary lipid nanoparticle delivery system known as LUNAR® to deliver its RNA medicines to cells.

History

Arcturus Therapeutics was founded in 2013 by Joseph Payne and Pad Chivukula. The company was initially based in San Diego, California. In 2020, Arcturus Therapeutics began clinical trials for a COVID-19 vaccine, known as ARCT-021.

Technology

Arcturus Therapeutics uses a proprietary lipid nanoparticle delivery system, LUNAR®, to deliver RNA medicines to cells. This technology allows for the targeted delivery of RNA medicines to specific cells in the body. The company also utilizes a proprietary RNA engineering platform, STARR™, to create RNA medicines that can be used to treat a variety of diseases.

Products

Arcturus Therapeutics has several products in its pipeline, including treatments for rare diseases, viral infections, and liver diseases. The company's most advanced product is ARCT-021, a vaccine for COVID-19 that is currently in clinical trials.

Clinical Trials

Arcturus Therapeutics has conducted several clinical trials to test the safety and efficacy of its products. The most notable of these is the ongoing trial for ARCT-021, the company's COVID-19 vaccine.

See Also

• Biotechnology
• RNA medicines
• Lipid nanoparticle
• COVID-19 vaccine

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!